NASDAQ:TXG 10x Genomics (TXG) Stock Price, News & Analysis $51.70 -5.68 (-9.90%) Closing price 11/20/2026 03:58 PM EasternExtended Trading$52.36 +0.66 (+1.28%) As of 11/20/2026 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About 10x Genomics Stock (NASDAQ:TXG) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get 10x Genomics alerts:Sign Up Key Stats Today's Range$51.30▼$56.4450-Day Range$51.70▼$97.7452-Week Range$15.18▼$102.81Volume3.23 million shsAverage Volume3.07 million shsMarket Capitalization$6.80 billionP/E RatioN/ADividend YieldN/APrice Target$68.40Consensus RatingHold Company Overview 10x Genomics, Inc. develops technology for studying biological systems at single-cell and spatial resolution. Its instruments, consumables and software help researchers analyze gene expression and other features of cells while preserving information about their location within tissue. The company’s product platforms include Chromium for single-cell analysis, Visium for spatial gene-expression analysis and Xenium for in situ analysis of gene activity within tissue samples. Its tools are used in areas such as immunology, neuroscience, cancer research and drug discovery. Founded in 2012 and headquartered in Pleasanton, California, 10x Genomics serves research and clinical customers around the world, including academic institutions, biotechnology and pharmaceutical companies, and other research organizations. Co-founder Serge Saxonov has served as the company’s chief executive officer.AI Generated. May Contain Errors. Read More 10x Genomics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks62nd Percentile Overall ScoreTXG MarketRank™: 3.08458409314 of 5 stars10x Genomics scored higher than 62% of companies evaluated by MarketBeat, and ranked 314th out of 837 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.1 / 5Analyst RatingHold Consensus Rating10x Genomics has received a consensus rating of Hold. The company's average rating score is 2.22, and is based on no strong buy ratings, 5 buy ratings, 12 hold ratings, and 1 sell rating.Upside Potential10x Genomics has a consensus price target of $68.40, representing about 32.3% upside from its current price of $51.70.Amount of Analyst Coverage10x Genomics has been the subject of 14 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about 10x Genomics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for 10x Genomics are expected to grow in the coming year, from ($0.67) to ($0.60) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of 10x Genomics is -99.42, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of 10x Genomics is -99.42, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share Ratio10x Genomics has a P/B Ratio of 8.12. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted10.50% of the float of 10x Genomics has been sold short.Short Interest Ratio / Days to Cover10x Genomics has a short interest ratio ("days to cover") of 4.13.Change versus previous monthShort interest in 10x Genomics has recently decreased by 2.04%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend Yield10x Genomics does not currently pay a dividend.Dividend Growth10x Genomics does not have a long track record of dividend growth. News and Social Media2.9 / 5News Sentiment0.60 News Sentiment10x Genomics has a news sentiment score of 0.60. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.41 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 4 news articles for 10x Genomics this week, compared to 6 articles on an average week.Search InterestOnly 6 people have searched for TXG on MarketBeat in the last 30 days. This is a decrease of -74% compared to the previous 30 days.MarketBeat Follows8 people have added 10x Genomics to their MarketBeat watchlist in the last 30 days. This is an increase of 60% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, 10x Genomics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $12,604,970.00 in company stock.Percentage Held by Insiders8.84% of the stock of 10x Genomics is held by insiders.Percentage Held by Institutions84.68% of the stock of 10x Genomics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about 10x Genomics' insider trading history. Receive TXG Stock News and Ratings via Email Sign-up to receive the latest news and ratings for 10x Genomics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. TXG Stock News HeadlinesACHR, LUNR, TXG: Cathie Wood Sells $6.1M of One Growth Stock, Buys the Other TwoNovember 18, 2026 | tipranks.com10x Genomics Expands Global Research in Blood-Based Diagnostics for Autoimmune Disease with Two New CollaborationsNovember 16, 2026 | prnewswire.comWhat the hell is going on?Porter Stansberry says President Trump is quietly replacing the U.S. dollar without a vote in Congress, and the shift is already underway. The dollar has lost 88% of its purchasing power since it was untethered from gold, and Fortune calls the current change the biggest shift in the world's relationship with the dollar in a generation. Stansberry says a similar reset is planned to be unveiled in Miami as soon as this December. Watch Porter Stansberry's full broadcast to see which companies could be affected.November 22 at 1:00 AM | Porter & Company (Ad)10x Genomics (NASDAQ:TXG) CEO Sells $1,949,900.00 in StockNovember 16, 2026 | americanbankingnews.comInsider Selling: 10x Genomics (NASDAQ:TXG) CEO Sells $1,949,900.00 in StockNovember 15, 2026 | insidertrades.com10x Genomics (NASDAQ: TXG) CEO sells shares and keeps a large stakeNovember 15, 2026 | americanbankingnews.com10x Genomics (NASDAQ:TXG) Stock Rating Upgraded by Wall Street ZenNovember 14, 2026 | americanbankingnews.comStephens Remains a Hold on 10x Genomics (TXG)November 12, 2026 | theglobeandmail.comSee More Headlines TXG Stock Analysis - Frequently Asked Questions How have TXG shares performed this year? 10x Genomics' stock was trading at $16.31 at the beginning of 2026. Since then, TXG shares have increased by 217.0% and is now trading at $51.6970. How were 10x Genomics' earnings last quarter? 10x Genomics (NASDAQ:TXG) released its quarterly earnings results on Thursday, November, 5th. The company reported ($0.15) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.27) by $0.12. The firm's quarterly revenue was up 1.1% on a year-over-year basis. Read the conference call transcript. When did 10x Genomics IPO? 10x Genomics (TXG) raised $370 million in an IPO on Thursday, September 12th 2019. The company issued 10,000,000 shares at a price of $36.00-$38.00 per share. J.P. Morgan, Goldman Sachs and BofA Merrill Lynch served as the underwriters for the IPO and Cowen was co-manager. Who are 10x Genomics' major shareholders? 10x Genomics' top institutional investors include Goldman Sachs Group Inc. (2.61%), State Street Corp (2.15%), Sumitomo Mitsui Trust Group Inc. (1.73%) and First Trust Advisors LP (0.35%). Insiders that own company stock include Serge Saxonov, Benjamin J Hindson, John R Stuelpnagel, Adam Taich, Justin J Mcanear, James Wilbur, Alan Mateo and Shehnaaz Suliman. View institutional ownership trends. How do I buy shares of 10x Genomics? Shares of TXG stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of 10x Genomics own? Based on aggregate information from My MarketBeat watchlists, some other companies that 10x Genomics investors own include Tesla (TSLA), NVIDIA (NVDA), CRISPR Therapeutics (CRSP), Palantir Technologies (PLTR), CrowdStrike (CRWD), Advanced Micro Devices (AMD) and Block (XYZ). Company Calendar Last Earnings11/05/2026Today11/22/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (2w+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 For the last 2 weeks, TXG's financial health has been in the Yellow zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Life Sciences Tools & Services Sub-IndustryLife Sciences Tools & Services Current SymbolNASDAQ:TXG CIK1770787 Webwww.10xgenomics.com Phone925-401-7300FaxN/AEmployees1,178Year Founded2012Price Target and Rating Average Price Target for 10x Genomics$68.40 High Price Target$110.00 Low Price Target$17.00 Potential Upside/Downside+32.3%Consensus RatingHold Rating Score (0-4)2.22 Research Coverage18 Analysts Profitability EPS (Trailing Twelve Months)($0.52) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$43.54 million Net Margins-10.84% Pretax Margin-10.53% Return on Equity-8.19% Return on Assets-6.46% Debt Debt-to-Equity RatioN/A Current Ratio5.12 Quick Ratio4.66 Sales & Book Value Annual Sales$618.58 million Price / Sales10.99 Cash FlowN/A Price / Cash FlowN/A Book Value$6.37 per share Price / Book8.12Miscellaneous Outstanding Shares131,534,000Free Float119,906,000Market Cap$6.80 billion OptionableOptionable Beta2.03 Social Links The 7 Best High-Yield Dividend Stocks for 2027Looking for higher dividend income in 2027? Discover seven high-yield dividend stocks with attractive payouts, proven dividend histories and growth potential.Get This Free Report This page (NASDAQ:TXG) was last updated on 11/20/2026 by MarketBeat.com Staff. From Our PartnersWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredWhat the hell is going on?Porter Stansberry says President Trump is quietly replacing the U.S. dollar without a vote in Congress, and th...Porter & Company | SponsoredYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredCFA: Bank of America Said THISOn January 24th, 2022, Bank of America told Bloomberg something that should terrify every American with a savi...Decentralized Masters | SponsoredThe warning signs most investors see too lateDr. Martin D. Weiss has publicly predicted six major American crashes since founding Weiss Ratings in 1971. ...Weiss Ratings | SponsoredURGENT: If you own a home, please review the map below.More than 1,300 red dots are scattered across the country, and 2,800 more are already on the way. Jim Rickards...Paradigm Press | SponsoredEvery Starlink dish pays this stockThere's a chip inside every Tesla and Starlink dish that Elon doesn't own. He pays royalties to use it. Now...Behind the Markets | SponsoredA quick test most investors failCan you defend your biggest holding? Seeking Alpha Premium gives you its Quant valuation grade versus its sect...Seeking Alpha | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding 10x Genomics Please log in to your account or sign up in order to add this asset to your watchlist. Share 10x Genomics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.